DeepMed Research

Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy

Phase 1

Recruiting

Conditions: Peanut Allergy

Interventions: Drug: Prebiotic
Drug: Placebo

First Posted Date: 2021-12-01

Last Posted Date: 2024-05-10

Lead Sponsor: University of Chicago

Target Recruit Count: 30

Registration Number: NCT05138757

Locations: 🇺🇸
Comer Children's Hospital, Chicago, Illinois, United States
🇺🇸
University of Chicago- Department of Pediatrics, Hyde Park, Illinois, United States

Drug Effects on Interpersonal Interaction

Early Phase 1

Completed

Conditions: Interaction, Social

Interventions: Drug: MDMA
Drug: placebo oral tablet

First Posted Date: 2021-11-17

Last Posted Date: 2022-06-15

Lead Sponsor: University of Chicago

Target Recruit Count: 30

Registration Number: NCT05123716

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

Phase 1

Recruiting

Conditions: HPV Positive Oropharyngeal Squamous Cell Carcinoma
Head and Neck Cancer
Human Papilloma Virus
HPV

Interventions: Drug: HB-201
Drug: HB-202
Drug: Carboplatin
Drug: Paclitaxel
Procedure: Transoral Robotic Surgery

First Posted Date: 2021-11-05

Last Posted Date: 2024-05-09

Lead Sponsor: University of Chicago

Target Recruit Count: 98

Registration Number: NCT05108870

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Intermuscular Coherence as a Biomarker for ALS

Recruiting

Conditions: Amyotrophic Lateral Sclerosis

First Posted Date: 2021-11-03

Last Posted Date: 2024-08-06

Lead Sponsor: University of Chicago

Target Recruit Count: 650

Registration Number: NCT05104710

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸
Washington University Medical Center, Saint Louis, Missouri, United States

and more 1 locations

Anesthesia Consent Process

Withdrawn

Conditions: Anesthesia
Consent Retention
Patient Satisfaction
Anesthesia Risks
Anesthesia Consent

First Posted Date: 2021-11-01

Last Posted Date: 2024-07-01

Lead Sponsor: University of Chicago

Registration Number: NCT05102487

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Collaborative Urological Prosthetics Investigation Directive Research Group

Early Phase 1

Active, not recruiting

Conditions: Erectile Dysfunction
Penile Prosthesis Infection

Interventions: Drug: Doxycycline
Drug: Ciprofloxacin
Drug: Augmentin
Drug: Bactrim

First Posted Date: 2021-10-29

Last Posted Date: 2025-03-10

Lead Sponsor: University of Chicago

Target Recruit Count: 800

Registration Number: NCT05100654

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Returning Genetic Results on Arsenic Susceptibility

Not Applicable

Completed

Conditions: Arsenic Exposure

Interventions: Other: Personal information on genetic susceptibility to arsenic toxicity
Other: standard information on arsenic exposure reduction

First Posted Date: 2021-10-08

Last Posted Date: 2024-05-08

Lead Sponsor: University of Chicago

Target Recruit Count: 300

Registration Number: NCT05072132

Locations: 🇧🇩
UChicago Research Bangladesh, Dhaka, Dhaka-1230, Bangladesh

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Phase 2

Recruiting

Conditions: Lung Cancer
Small-cell Lung Cancer
Extensive-stage Small-cell Lung Cancer

Interventions: Radiation: Ablative Radiation
Drug: Durvalumab
Drug: Etoposide
Drug: Carboplatin

First Posted Date: 2021-10-05

Last Posted Date: 2025-01-27

Lead Sponsor: University of Chicago

Target Recruit Count: 49

Registration Number: NCT05068232

Locations: 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

Phase 2

Completed

Conditions: Peritoneal Mesothelioma
Mesothelioma

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2021-09-10

Last Posted Date: 2024-01-03

Lead Sponsor: University of Chicago

Target Recruit Count: 2

Registration Number: NCT05041062

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Not Applicable

Active, not recruiting

Conditions: Non-hodgkin Lymphoma
Hodgkin Lymphoma
Lymphoma

Interventions: Radiation: Radiation - Dose Level 3
Radiation: Radiation - Dose Level 2
Radiation: Radiation - Dose Level 0
Radiation: Radiation - Dose Level 1
Radiation: Radiation - Dose Level 4

First Posted Date: 2021-08-25

Last Posted Date: 2024-11-12

Lead Sponsor: University of Chicago

Target Recruit Count: 30

Registration Number: NCT05019976

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy